RxDoctor Payments Data

Alexander Lustberg, MD

Gastroenterology · Santa Rosa, CANPI 1225009301

Payments from drug & device makers

$7,415in general payments, 2019–2025

Across 58 payments — averaging $127.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Medical Systems Corporation$4K
  • Boston Scientific$3K
  • AbbVie$119
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$112
  • Pfizer$74
  • Takeda Pharmaceuticals U.S.A., Inc.$70
  • plus $303 from 8 others

What the payments were for

  • Consulting fees$3,63449%
  • Travel & lodging$2,10828%
  • Food & beverage$1,64322%
  • Education$300%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,415 in reported general payments places this provider in the 70th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$174,553
Medicare patients
542
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$399,097
XifaxanRifaximin35$113,458
CreonLipase/Protease/Amylase27$101,083
ZenpepLipase/Protease/Amylase11$31,802
LinzessLinaclotide36$29,131
MotegrityPrucalopride Succinate14$13,578
Dexlansoprazole DrDexlansoprazole57$13,568
Mesalamine39$9,448
TrulancePlecanatide12$6,427
Budesonide EcBudesonide30$2,899
Ursodiol39$2,693
Omeprazole202$2,504
Budesonide DrBudesonide47$2,443
Pantoprazole Sodium160$2,209
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg79$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$56$399,09715 claims
AbbVieCreon, Linzess$119$130,21463 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$112$119,88547 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$70$13,57814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →